With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class.

Dawn Firmin, ILC Therapeutics Chief Operating Officer, spoke with Manufacturing Chemist about how the Company is pioneering a novel drug class called hybrid interferons.

 

Read the full article here: https://manufacturingchemist.com/hybrid-interferons-developing-a-novel-drug-class